Nasal Drug Delivery

SNBL’s nasal drug delivery platform is a proprietary system consisting of powder carrier technology and delivery device technology.

Expertise in Nasal Delivery

3D Nasal Cast Model

preview
next

Platform Technology

Proprietary Nasal Drug Delivery System

SNBL has developed a proprietary nasal drug delivery technology, μco™ System, consisting of a powder carrier technology (μco™ Carrier) designed for increased drug absorption through its muco-adhesive properties and a delivery device technology designed for simple use, and complete and consistent delivery of intranasal powder formulations.
Our technology can be applied to a wide range of drugs, including small molecules, peptides, and biologics. It can be utilized for improved systemic drug absorption, enhanced muco-immunity for a vaccine, or for enabling drug delivery to the brain through the olfactory area.

Platform Technology

The μco™ System is a nasal drug delivery platform comprised of powder carrier technology and delivery device technology.

Powder Formulation Technology
μco™ Carrier

  • Powder carrier
  • Use of safety-proven pharmaceutical additives (FDA GRAS*)
  • Excellent safety profile in clinical trials in more than 150 subjects
  • Compatibility with the mucosal membrane
  • Muco-adhesive
  • Versatility of application to a wide range of drugs
  • Increased stability of formulation at room temperature

*GRAS: Generally Recognized as Safe: The U.S. Food and Drug Administration (FDA) designation that a chemical or substance added to food is generally recognized to be safe.

Delivery Device Technology
Fit-lizer™

  • Single-use, disposable
  • Self-administration or by caregiver
  • Ergonomic design
  • Simple operation and easy to use
  • Complete and consistent delivery

Special Analyses for Nasal Drug Delivery System

Special analyses for the development of our nasal drug delivery technology

  • Primary particle size
  • Secondary particle size
  • Aerodynamic particle size
  • Plume geometry
  • Spray pattern
  • Nasal delivery devices for animal
  • Distribution analysis with human nasal cavity cast model
  • Distribution analysis with non-human primate nasal cavity model

Publication

Journal/Magazine

  • Mizutani A, et al. Indirect SPECT Imaging Evaluation for Possible Nose-to-Brain Drug Delivery Using a Compound with Poor Blood-Brain Barrier Permeability in Mice. Pharmaceutics. 2022 May 10;14(5):1026.
  • Torikai Y, et al. Evaluation of Systemic and Mucosal Immune Responses Induced by a Nasal Powder Delivery System in Conjunction with an OVA Antigen in Cynomolgus Monkeys. J Pharm Sci. 2021 May;110(5):2038-2046.
  • Albrecht D, et al. A Phase1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. Headache. 2020;0: 1-12
  • Milewski M,et al. Rapid Absorption of Dry-Powder Intranasal Oxytocin. Pharm Res. 2016;33: 1936-1944
  • Haruta S. PAIN MANAGEMENT - Rapid Action Therapy in Pain Relief: Potential for Nasal Delivery Systems. Drug Development and Delivery Magazine. July/August 2013 Issue
  • Haruta S. INTERVIEW - SNBL, Ltd.: Innovation in Drug Delivery Enabled Through a Unique Business Model. Drug Development and Delivery Magazine. May 2013 Issue
  • Haruta S. A Nasal Delivery Solution to the Challenges in Biotherapeutic Delivery. ONdrugDelivery Magazine. December 2012 Issue
  • Haruta S. How Nasal Delivery Can Meet the Changing Needs of Patients & the Drug Development Industry. ONdrugDelivery Magazine. November 2012 Issue
  • Haruta S. Special CRO Services Generated through R&D of Proprietary Nasal Delivery System. ONdrugDelivery Magazine. September 2012 Issue
  • Haruta S. ADVANCED DELIVERY DEVICES - Meeting the Needs of Nasal Delivery Devices for Powder Formulations. Drug Development and Delivery Magazine. June 2012 Issue
  • Haruta S. Achieving the Potential of Nasal Drug Delivery. ONdrugDelivery Magazine. April 2012 Issue